Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics (CHINOOK)
view all Clinical Trials
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.
Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication.
Patients who complete treatment will enter 4 weeks follow-up period.
For more information about this trial or to inquire about eligibility, email firstname.lastname@example.org or call 215-707-1359.